{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:09:33Z","timestamp":1768414173087,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.trim.2022.101778","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T21:07:15Z","timestamp":1672175235000},"page":"101778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Basiliximab is associated with a lower incidence of De novo donor-specific HLA antibodies in kidney transplant recipients: A single-center experience"],"prefix":"10.1016","volume":"77","author":[{"given":"Tambi","family":"Jarmi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousif","family":"Abdelmoneim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Jebrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Elrefaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.trim.2022.101778_bb0005","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/ki.2010.556","article-title":"Surveillance of alloantibodies after transplantation identifies the risk of chronic rejection","volume":"79","author":"Kimball","year":"2011","journal-title":"Kidney Int."},{"issue":"10","key":"10.1016\/j.trim.2022.101778_bb0010","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1097\/TP.0b013e3181a44206","article-title":"Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts","volume":"87","author":"Lachmann","year":"2009","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.trim.2022.101778_bb0015","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2215\/CJN.00700117","article-title":"Donor-specific antibodies in kidney transplant recipients","volume":"13","author":"Zhang","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"13","key":"10.1016\/j.trim.2022.101778_bb0020","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1302506","article-title":"Complement-binding anti-HLA antibodies and kidney-allograft survival","volume":"369","author":"Loupy","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.trim.2022.101778_bb0025","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1111\/ajt.12462","article-title":"Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA-drilling down on key sources of variation","volume":"13","author":"Reed","year":"2013","journal-title":"Am. J. Transplant."},{"issue":"3","key":"10.1016\/j.trim.2022.101778_bb0030","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/TP.0000000000002351","article-title":"Comparison of two Luminex single-antigen bead flow cytometry assays for detection of donor-specific antibodies after renal transplantation","volume":"103","author":"Bertrand","year":"2019","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.trim.2022.101778_bb0035","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1600-6143.2012.04013.x","article-title":"Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant","volume":"12","author":"Wiebe","year":"2012","journal-title":"Am. J. Transplant."},{"issue":"5","key":"10.1016\/j.trim.2022.101778_bb0040","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/j.1600-6143.2012.04016.x","article-title":"Below the waterline -- the danger of de novo donor-specific HLA antibodies","volume":"12","author":"Kokko","year":"2012","journal-title":"Am. J. Transplant."},{"issue":"6","key":"10.1016\/j.trim.2022.101778_bb0045","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/ajt.12212","article-title":"De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients","volume":"13","author":"Kaneku","year":"2013","journal-title":"Am. J. Transplant."},{"issue":"2","key":"10.1016\/j.trim.2022.101778_bb0050","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1399-0012.2009.01056.x","article-title":"Non-adherence to immunosuppressive medication in renal transplant recipients within the scope of the integrative model of behavioral prediction: a cross-sectional study","volume":"24","author":"Schmid-Mohler","year":"2010","journal-title":"Clin. Transpl."},{"issue":"6","key":"10.1016\/j.trim.2022.101778_bb0055","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/TP.0000000000000031","article-title":"Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibodies in moderately sensitized renal transplant recipients","volume":"97","author":"Brokhof","year":"2014","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.trim.2022.101778_bb0060","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","article-title":"A simple salting out procedure for extracting DNA from human nucleated cells","volume":"16","author":"Miller","year":"1988","journal-title":"Nucleic Acids Res."},{"issue":"10","key":"10.1016\/j.trim.2022.101778_bb0065","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/TP.0b013e3182139da1","article-title":"Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes","volume":"91","author":"Cooper","year":"2011","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.trim.2022.101778_bb0070","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/ki.2012.190","article-title":"Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation","volume":"82","author":"DeVos","year":"2012","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.trim.2022.101778_bb0075","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/TP.0b013e3182543950","article-title":"De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy","volume":"94","author":"Willicombe","year":"2012","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.trim.2022.101778_bb0080","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/TP.0000000000000869","article-title":"The influence of immunosuppressive agents on the risk of De novo donor-specific HLA antibody production in solid organ transplant recipients","volume":"100","author":"O\u2019Leary","year":"2016","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.trim.2022.101778_bb0085","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/TP.0b013e31827d62e3","article-title":"Incidence and impact of de novo donor-specific alloantibody in primary renal allografts","volume":"95","author":"Everly","year":"2013","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.trim.2022.101778_bb0090","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.coi.2005.07.018","article-title":"Humoral theory of transplantation: further evidence","volume":"17","author":"Terasaki","year":"2005","journal-title":"Curr. Opin. Immunol."},{"issue":"5","key":"10.1016\/j.trim.2022.101778_bb0095","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.4049\/jimmunol.1203261","article-title":"In kidney transplant patients, alemtuzumab but not basiliximab\/low-dose rabbit anti-thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-HLA antibody development","volume":"191","author":"Todeschini","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.trim.2022.101778_bb0100","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/164_2021_546","article-title":"Immunosuppression and kidney transplantation","volume":"272","author":"Kamal","year":"2022","journal-title":"Handb. Exp. Pharmacol."},{"issue":"28","key":"10.1016\/j.trim.2022.101778_bb0105","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.2174\/1381612826666200521142448","article-title":"Immunosuppression in kidney transplantation: state of the art and current protocols","volume":"26","author":"Bauer","year":"2020","journal-title":"Curr. Pharm. Des."},{"issue":"8","key":"10.1016\/j.trim.2022.101778_bb0110","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1097\/00007890-200210270-00025","article-title":"All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies","volume":"74","author":"Lee","year":"2002","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.trim.2022.101778_bb0115","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1097\/00007890-200104270-00017","article-title":"Impact of donor-specific antibodies on chronic rejection occurrence and graft loss in renal transplantation: posttransplant analysis using flow cytometric techniques","volume":"71","author":"Piazza","year":"2001","journal-title":"Transplantation"},{"issue":"12","key":"10.1016\/j.trim.2022.101778_bb0120","doi-asserted-by":"crossref","first-page":"787","DOI":"10.14740\/jocmr4369","article-title":"The impact of different induction immunosuppressive therapy on long-term kidney transplant function when measured by Iothalamate clearance","volume":"12","author":"Jarmi","year":"2020","journal-title":"J. Clin. Med. Res."},{"issue":"51","key":"10.1016\/j.trim.2022.101778_bb0125","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000028159","article-title":"Early outcomes and long-term survival after kidney transplantation in elderly versus younger recipients from the same donor in a matched-pairs analysis","volume":"100","author":"Jankowska","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.trim.2022.101778_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.612576","article-title":"Editorial: transplantation of marginal organs-immunological aspects and therapeutic perspectives","volume":"11","author":"Susal","year":"2020","journal-title":"Front. Immunol."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327422002520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327422002520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:01:20Z","timestamp":1760810480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327422002520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":26,"alternative-id":["S0966327422002520"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2022.101778","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Basiliximab is associated with a lower incidence of De novo donor-specific HLA antibodies in kidney transplant recipients: A single-center experience","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2022.101778","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101778"}}